Recent Publications

• Belch A, Kouroukis CT, Crump M, Sehn L, Gascoyne RD, Klasa R, Powers Wright J, Eisenhauer EA.  A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150.  Ann Oncol. 2006 Sep 13; [Epub ahead of print] PMID: 16971665 [PubMed – as supplied by publisher].
• Savage KJ. Al-Rajhi N. Voss N. Paltiel C. Klasa R. Gascoyne RD. Connors JM. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. [Journal Article] Annals of Oncology. 17(1):123-30, 2006 Jan.
• Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, Gascoyne RD, Connors JM.  Revised International Prognostic Index (R-IPI) is a better predictor of outcome  than the Standard IPI for patients with DLBCL treated with R-CHOP.Blood. 2006 Nov 14; [Epub ahead of print] PMID: 17105812 [PubMed – as supplied by publisher].
• Tucker CA. Bebb G. Klasa RJ. Chhanabhai M. Lestou V. Horsman DE. Gascoyne RD. Wiestner A. Masin D. Bally M. Williams ME. Four human t(11;14)(q13;q32)-containing cell lines having classic and variant features of Mantle Cell Lymphoma. [Journal Article] Leukemia Research. 30(4):449-57, 2006 Apr.
• Van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, Jack A, Van’Veer M, Vranovsky A, Holte H, van Glabbeke M, Teodorovic I, Rozewicz C, Hagenbeek A. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.  Blood. 2006 Nov 15;108(10):3295-301. Epub 2006 Jul 27.  PMID: 16873669 [PubMed – in process].
• Waterhouse DN. Gelmon KA. Klasa R. Chi K. Huntsman D. Ramsay E. Wasan E. Edwards L. Tucker C. Zastre J. Zhang YZ. Yapp D. Dragowska W. Dunn S. Dedhar S. Bally MB. Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers. [Journal: Review] Current Cancer Drug Targets. Vol. 6(6)(pp 455-489), 2006.
• Chiu GN, Edwards LA, Kapanen AI, Malinen MM, Dragowska WH, Warburton C, Chikh GG, Fang KY, Tan S, Sy J, Tucker C, Waterhouse DN, Klasa R, Bally MB.  Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs.  Mol Cancer Ther 2007;6:844-55.
• Sehn LH. Berry B. Chhanabhai M. Fitzgerald C. Gill K. Hoskins P. Klasa R. Savage KJ. Shenkier T. Sutherland J. Gascoyne RD. Connors JM. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. [Journal Article. Research Support, Non-U.S. Gov’t] Blood. 109(5):1857-61, 2007 Mar 1.
• Wilson KS. Sehn LH. Berry B. Chhanabhai M. Fitzgerald CA. Gill KK. Klasa R. Skinnider B. Sutherland J. Connors JM. Gascoyne RD. CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma.[see comment]. [Evaluation Studies. Journal Article. Research Support, Non-U.S. Gov’t] Leukemia & Lymphoma. 48(6):1102-9, 2007 Jun.
• Murray N. Klasa R. Reconsideration of American Society of Clinical Oncology/American Society of Hematology Erythropoiesis-stimulating Agent Guidelines. [Letter] Journal of Clinical Oncology. 26(18):3096-7, 2008 Jun 20.
• Tucker CA. Kapanen AI. Chikh G. Hoffman BG. Kyle AH. Wilson IM. Masin D. Gascoyne RD. Bally M. Klasa RJ. Silencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor-kappaB, p53, bax, and p27 levels. [Journal Article. Research Support, Non-U.S. Gov’t] Molecular Cancer Therapeutics. 7(4):749-58, 2008 Apr.